{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T09:03:19Z","timestamp":1770973399782,"version":"3.50.1"},"reference-count":5,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["DTB"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>\n                  <jats:bold>Overview of:<\/jats:bold>\nSims JR, Zimmer JA, Evans CD, et al. Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 2023;330:512-27\n<\/jats:p>","DOI":"10.1136\/dtb.2024.000020","type":"journal-article","created":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T13:20:22Z","timestamp":1712323222000},"page":"67-67","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Donanemab in early symptomatic Alzheimer\u2019s disease"],"prefix":"10.1136","volume":"62","member":"239","published-online":{"date-parts":[[2024,4,5]]},"reference":[{"key":"2025082622564544000_62.5.67.1","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"2025082622564544000_62.5.67.2","unstructured":"Public Citizen. Outrage of the month: FDA approval of lecanemab for Alzheimer\u2019s disease [online]. 2024. Available: https:\/\/www.citizen.org\/article\/outrage-of-the-month-fda-approval-of-lecanemab-for-alzheimers-disease\/ [Accessed 27 Mar 2024]."},{"key":"2025082622564544000_62.5.67.3","unstructured":"European Medicines Agency . Aduhelm [online]. 2022. Available: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/aduhelm [Accessed 27 Mar 2024]."},{"key":"2025082622564544000_62.5.67.4","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.q281","article-title":"Aduhelm: Biogen abandons Alzheimer\u2019s drug after controversial approval left it unfunded by Medicare","volume":"384","author":"Dyer","year":"2024","journal-title":"BMJ"},{"key":"2025082622564544000_62.5.67.5","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1001\/jama.2023.11704","article-title":"Donanemab for Alzheimer disease \u2013 who benefits and who is harmed?","volume":"330","author":"Manly","year":"2023","journal-title":"JAMA"}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2024.000020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T05:56:54Z","timestamp":1756274214000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2024.000020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,5]]},"references-count":5,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,4,25]]},"published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1136\/dtb.2024.000020"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2024.000020","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"value":"0012-6543","type":"print"},{"value":"1755-5248","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,5]]}}}